Authoritative interpretation! How do pharmaceutical companies coordinate the relationship between quality and cost? The key is to look at these 4 points!

Introduction: Pharmaceutical Zhi interview special interview with China Chemical and Pharmaceutical Industry Association Executive Chairman Pan Guangcheng, listen to the industry how to help.
. Recently, Shanghai Sunshine Pharmaceutical Procurement Network issued a "notice on the implementation of some of the basic information collection work related to drugs" (hereinafter referred to as "Notice"), meaning that the third batch of the national collection landed, 86 drug joint procurement offices began to collect information.
, what impact will the volume purchase have on pharmaceutical companies? How can pharmaceutical companies seize the policy opportunity to win the price war and coordinate the relationship between quality and cost? On these issues, Pharmaceutical Intelligence interview special interview with China Chemical And Pharmaceutical Industry Association Executive Chairman Pan Guangcheng, listen to the industry how to recruit.
Pan Guangcheng: What reforms have China's pharmaceutical industry undergone and what major achievements have been made? President Pan: In the 40 years since the reform and opening-up, China has undergone a series of reforms, such as the implementation of the classification management of prescription and over-the-counter drugs, the implementation of the GMP, the implementation of the system of practicing pharmacists, the implementation of consistent evaluation of the quality and efficacy of generic drugs, the implementation of the basic drug system, the implementation of the drug market licensing system and a series of reforms, the pharmaceutical industry has made great progress.
China's API production and export ranks first in the world, China has become the world's second largest pharmaceutical market, China's pharmaceutical science and technology innovation has become the world's second tier, China has become the world's pharmaceutical power.
: Affected by the epidemic, the first half of China's pharmaceutical industry development? President Pan: Affected by the epidemic, the first quarter of the pharmaceutical industry economic indicators are not ideal, but in the second quarter, with the full resumption of production, all economic indicators have increased significantly.
according to the quarterly report of the National Bureau of Statistics, the country's pharmaceutical industry achieved operating income of 1.2 trillion yuan in January-June, up 0.22% YoY, and a total profit of 185 billion yuan.
year-on-year growth of 9.06 percent, and the value of export deliveries was 136.5 billion yuan.
year-on-year growth of 31.89 percent.
the present, from the domestic point of view, affected by the epidemic, many hospitals general outpatient clinic has not yet opened, affecting the domestic marketing of enterprises;
: How to win the epidemic resistance war, complete the pharmaceutical industry's year-round mission goals? President Pan: I have three suggestions.
is to ensure the production and supply of API.
China, as a large producer and exporter of API and intermediates, occupies an important position in the world market, and WHO is very concerned about the production and supply of CHINESE API and intermediates.
pharmaceutical enterprises should make urgent efforts to resume production, ensure quality, do a good job in the production and supply of API and intermediates, and contribute to the fight against the epidemic in China and the world.
is to increase research and development of new drugs.
to overcome the catastrope can not be separated from scientific development and technological innovation.
We should speed up the process of drug research and development, adhere to the emphasis of Chinese and Western medicines, accelerate the promotion of effective therapeutic drugs that have been developed and screened, especially to accelerate the detection of new testing reagents, antibody drugs and vaccines, in order to win the fight against the epidemic to provide strong scientific and technological support.
is to promote the transformation and upgrading of the industry.
through this outbreak, the digital and intelligent transformation and upgrading of the manufacturing industry will be accelerated.
pharmaceutical industry should be more active in the application of the industrial Internet for intelligent, digital transformation, to promote 5G, big data and other technologies in the pharmaceutical manufacturing industry, to promote the transformation and upgrading of the industry.
: The third batch of national procurement landing, in the national volume procurement and generic drug consistency evaluation background, will have any positive impact on China's pharmaceutical industry? President Pan: Through the evaluation of the consistent quality and efficacy of generic drugs, it will greatly improve the quality awareness of enterprises and scientific and technological innovation, and promote the transformation and upgrading of the industry to improve quality and efficiency.
For the quality of drugs, generic consistent evaluation requires generic drugs and the effect of the original research drugs consistent, will greatly improve the quality of generic drugs, for drug prices, volume procurement policy will reform the "kickback"-based marketing model, change the inflated drug prices, control the reasonable price range of drugs.
the same time, through the national volume procurement, will promote enterprises to increase investment in new products innovation, and eliminate a number of non-aggressive, not practical research and development enterprises.
through drug price formation mechanism based on drug economics, will promote the steady and rapid development of the industry.
: With volume procurement, a new round of price war or inevitable, how do you think pharmaceutical companies coordinate the relationship between quality and cost? What should the pharmaceutical industry focus on?
Pan: Drug price war is inevitable, but also a law of medical development.
drugs must serve the public, and the prices acceptable to the public are not sky-high.
price war, medicines must survive on quality.
my opinion, the four characteristics of drugs or key points, one is safety, two is effective, three is accessable, four is quality control.
drug quality and safety as the lifeline of pharmaceutical companies, and can not be insurmountable.
if enterprises cause major quality and safety accidents in order to reduce costs, they will be severely punished.
, improving drug traceability is the key to ensuring the quality of medicines.
to encourage pharmaceutical production enterprises to assume the main role in drug traceability, innovative ideas, the use of unique identification and mature standards, to achieve the source can be identified, to traceable, responsible drug traceability.
development of drug traceability system to adhere to: First, patient drug safety traceability, and actively adopt international coding standards;
: What are the new requirements for China's pharmaceutical industry and enterprises after China joined the International Association of Technical Requirements for the Registration of Human Medicines (ICH)? What guidance has the country and industry done? President Pan: China has officially joined ICH, drug regulation is in line with the international advanced regulatory market, and more and more local enterprises are required to integrate into the global system, which also tests the ability of local enterprises to learn and adapt to the rules of the world game.
pharmaceutical industry is a relatively high degree of internationalization of an industry.
We should strengthen international technology exchanges and cooperation, promote the organic combination of investment, technology and intelligence, achieve win-win cooperation, support enterprises to establish cross-border research and development cooperation platform, encourage international clinical research on new drugs, realize the international market for innovative drugs and participate in international competition, implement the requirements of the "Belt and Road" construction, promote pharmaceutical enterprises to go out and expand international cooperation, strengthen training, and vigorously promote the implementation of ICH landing in China.
through continuous innovation and development, China's pharmaceutical industry's industrial structure, innovation capacity, quality safety and security capabilities will be raised to a new level.
After China's accession to ICH, the work carried out by the state and industry: First, to maintain close contact with ICH and other relevant institutions;
interview with this issue of experts introduced Pan Guangcheng, senior engineer.
has served as a cadre and director of the Medical Devices Bureau of the Ministry of Health, director of the Personnel Department of the State Administration of Medicine, deputy director, director of the Department of Policy and Regulation, deputy general manager of China Medical Device Industry Corporation, secretary of the board of directors of China Pharmaceutical Group Corporation, and executive vice president of the China Chemical and Pharmaceutical Industry Association.
is currently an independent director of Tianjin Lisheng Pharmaceutical Co., Ltd., an independent director of Ha Pharmaceutical Group Co., Ltd., an independent director of Tianjin Kailai In Pharmaceutical Group Co., Ltd., and an executive director of the China Chemical Pharmaceutical Industry Association.
recommended reading: How to improve research and development efficiency, reduce costs? Experts put pulses on the most critical steps! You're going to die? With the volume of procurement led to change in the industry, expert drama through the consistency evaluation "inside"! Anti-new crown with code? How the computer can assist the authoritative interpretation of special effect drug research and development: CAR-T is effective against blood tumors, but the efficacy of solid tumors needs to be verified.